Heron Therapeutics | HRTX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 3.64M 775K 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
Eisai JPY 1.96B 409M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 18.84M 1.24M 2026-06
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Omeros USD 4.05M 5.16M 2024-09
Pacira USD 3.62M 77K 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Veracyte USD 2K 1000 2023-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12